A niche API and pharmaceutical intermediates manufacturer with global regulatory approvals, strong R&D capabilities, and expanding manufacturing capacity – but how resilient and scalable is its revenue model? Anlon Healthcare IPO review will clear all your doubts.
The Indian pharmaceutical industry is undergoing a structural shift. With rising demand for APIs (Active Pharmaceutical Ingredients), growing nutraceutical consumption, and the global “China+1” sourcing strategy, Indian chemical manufacturers are gaining prominence. Against this backdrop, Anlon Healthcare, a Rajkot-based API and pharma intermediates manufacturer, is launching its IPO from 26–29 August 2025.
The company specialises in high-purity APIs and intermediates and has built a product portfolio spanning 65 commercialized products, 28 in the pilot stage, and 49 under laboratory testing. More importantly, Anlon is among the few Indian manufacturers of Loxoprofen Sodium Dihydrate, a globally relevant NSAID (non-steroidal anti-inflammatory drug).
With regulatory approvals from Brazil, Japan, and China, and 21 DMF filings across Europe, Russia, South Korea, Iran, and other jurisdictions, Anlon is not just a domestic supplier but an emerging global API contender.
👉 For investors evaluating the company, this Anlon Healthcare IPO review focuses on its business model, revenue streams, and operational backbone – the true drivers of long-term value creation.
1. Anlon Healthcare IPO Review: Business Model Analysis
Anlon Healthcare business model is designed around B2B supply of APIs and intermediates to pharmaceutical companies, with gradual diversification into custom synthesis services. It rests on four foundational pillars:
(a) Core Activities
- Manufacturing Pharma Intermediates, which serve as building blocks for APIs.
- Manufacturing APIs, which act as raw materials for finished dosage formulations (tablets, capsules, syrups).
- Supplying to multiple industries – Pharma, Nutraceuticals, Veterinary, and Personal Care.
- Recently entering custom manufacturing for complex or novel molecules, tailoring processes to client specifications.
(b) Value Proposition
- Compliance with international pharmacopoeia standards (IP, BP, EP, JP, USP).
- Strong environmental and safety credentials – a Zero Liquid Discharge facility, effluent treatment, and waste recycling partnerships.
- Regulatory credibility with DMF filings and approvals, enabling entry into regulated and semi-regulated markets.
- Technical expertise in purity optimisation and impurity reduction, critical for regulated markets.
(c) Customer Stickiness
- Customer acquisition is slow due to lengthy approval cycles (DMFs, on-site audits, GMP inspections).
- Once approved, customers rarely switch suppliers because it requires fresh filings, re-validations, and regulatory costs.
- This creates high entry and exit barriers, giving Anlon repeat orders and long-term partnerships.
(d) Scalability
- Installed capacity: 400 MTPA, running at 84% utilisation in FY25.
- Expansion underway: 700 MTPA new plant, raising total to 1,100 MTPA.
- Strong R&D pipeline with 77 products in pilot/lab stage, ensuring scalability.
💡 As highlighted in this IPO review, Anlon’s model is sticky, compliant, and scalable, though it remains vulnerable to customer concentration.
2. Revenue Streams
Anlon Healthcare revenue streams are diversified by products, customers, and geography, though some areas remain underdeveloped.
(a) By-products
- APIs: Major contributor, with products like Loxoprofen Sodium Dihydrate, Ketoprofen, Dexketoprofen Trometamol, Desloratadine, Rivaroxaban, Silodosin, etc.
- Pharma Intermediates: Building blocks such as 3-(1-cyanoethyl)benzoic acid, Ketonitrile, Loxoprofen Acid.
- Nutraceutical Ingredients: L-Carnitine Tartrate, L-Carnitine Fumarate.
- Personal Care APIs: Piroctone Olamine (anti-dandruff).
- Veterinary APIs: Animal health formulations.
📌 Note: APIs dominate current revenues, but diversification into nutraceuticals and personal care reduces cyclicality.
(b) By Customers
- FY23–25: Top 10 customers contribute ~75–78% of revenues.
- Customer base shrank from 48 (FY23) to 38 (FY25), while revenue per client grew.
- Note: Deeper relationships with fewer clients, but high dependence on key accounts.
(c) By Geography
- Domestic sales dominate: INR 116.39 crore in FY25.
- Exports just ~INR 3.9 crore (3%), despite multiple DMF filings.
- Present in 15 countries, including Germany, Italy, UK, Japan, Brazil.
From the Anlon Healthcare IPO review, it is clear that the company remains largely a domestic API supplier, but has significant room to scale internationally once regulatory approvals translate into sales.
(d) Emerging Stream – Custom Manufacturing
- Involves developing molecules per client specs, scaling from lab → pilot → commercial scale.
- Offers higher margins and long-term contracts.
- As of FY25, not monetised, but could become a powerful revenue engine.
(e) Pricing Mechanism
- Prices locked in purchase orders, quoted in INR/USD.
- Influenced by raw material prices, demand-supply balance, logistics, and credit terms.
Note: Limited pricing power, but customer stickiness ensures stability.
3. Manufacturing & Operations Backbone
Anlon’s operations provide the infrastructure credibility needed for global markets:
- Facility: Rajkot, Gujarat, spread over 5,059 sq. mtrs.
- Capacity: 400 MTPA, utilisation at 84% in FY25.
- Expansion: New 700 MTPA facility, within 400m of the current site.
- Equipment: Glass-lined & SS reactors, centrifuges, dryers, scrubbers, cooling towers, effluent treatment.
- Environmental: Zero Liquid Discharge (ZLD), effluent recycling, tie-ups with external waste firms.
In-house Capabilities
- 4 Testing Labs for QC, QA, and product development.
- 34-member QC team monitoring impurity reduction and compliance.
- Product pipeline: Grew from 10 products in 2018 → 65 in 2025, with 77 more under development.
4. Financial Performance & Efficiency
Anlon Healthcare has shown improved profitability despite volatility in revenue. The company’s financials highlight its transition from a debt-heavy small player to a more efficient and scalable manufacturer.
| Particulars | FY2023 | FY2024 | FY2025 | Trend/Remarks |
|---|---|---|---|---|
| Revenue from Operations | 112.88 | 66.58 | 120.29 | Volatile; FY24 dip due to lower utilization |
| EBITDA | 20.88 | 15.55 | 32.34 | Margins expanded steadily |
| EBITDA Margin (%) | 18.51% | 23.35% | 26.88% | Improved efficiency, cost control |
| Net Profit (PAT) | 5.82 | 9.66 | 20.52 | 92% CAGR (FY23–25) |
| PAT Margin (%) | 5.16% | 14.51% | 17.06% | Significant jump |
| Debt/Equity | 9.00 | 3.55 | 0.73 | Strong deleveraging |
| RONW (%) | 78.92 | 45.92 | 25.51 | Volatile; FY24 dip due to lower utilisation |
| ROCE (%) | 17.16 | 16.29 | 21.93 | Strong vs industry peers |
Insights:
- Revenue dip in FY24 was linked to capacity utilisation falling to 38%, but FY25 rebound shows scalability when utilisation improves (84%).
- Margins expanded as the company moved into higher-value APIs and controlled input costs.
- Balance sheet strengthened sharply; debt repayment is a clear IPO objective.
- ROCE above 20% indicates capital-efficient growth.
5. Growth Levers & Opportunities
Capacity Expansion
- Current capacity: 400 MTPA (almost fully utilised).
- New facility: 700 MTPA planned, taking the total to 1,100 MTPA.
- This expansion is the backbone of future scaling.
Product Pipeline Strength
- 65 commercialised products generating revenue.
- 28 pilot-stage products close to commercialisation.
- 49 laboratory-stage products representing future revenue streams.
Regulatory & Global Reach
- Approvals from Brazil, Japan, China.
- 21 DMFs filed across EU, Russia, South Korea, Iran, Jordan, Pakistan.
- Upcoming filings in US and Europe (Ketoprofen, Dexketoprofen).
Custom Manufacturing Services
- Tailored solutions for pharma companies — higher margins, customer stickiness.
- Still unmonetized, but offers long-term upside.
Industry Tailwinds
- Global China+1 diversification is boosting India’s API sector.
- Rising global demand for cost-efficient, high-quality APIs.
6. Anlon Healthcare IPO Review: Risks & Challenges
| Risk Factor | Details | Potential Impact |
|---|---|---|
| Customer Concentration | Top 10 clients = ~77% revenue | High dependency risk |
| Low Export Revenue | Only ~3% of sales despite global filings | Execution gap in scaling exports |
| Supplier Dependence | Top 10 suppliers = 90% of raw materials | Margin pressure if raw material prices spike |
| Long Approval Cycles | DMF filings, audits delay new revenue | Slower customer onboarding |
| Competition | Domestic peers & Chinese suppliers | Pressure on pricing & market share |
| Operational Risks | Regulatory compliance, safety standards | Plant shutdowns, reputational risk |
7. IPO Details & Utilisation of Proceeds
| Particulars | Details |
|---|---|
| IPO Size | INR 114 – 121 crore |
| Price Band | INR 86 – 91 per share |
| Fresh Issue | 1,33,00,000 shares (INR 114.38 – 121.03 crore) |
| Offer for Sale (OFS) | Nil |
| Lot Size | 164 shares (INR 14,924) |
| Listing | NSE, BSE |
| Retail Allocation | 10% |
Use of Proceeds:
- Expansion Capex (new plant): INR 30.7 Cr
- Debt repayment: INR 5 Cr
- Working capital: INR 43.2 Cr
- General corporate purposes: balance
👉 Focused on capacity + balance sheet clean-up — both positives for investors.
8. Anlon Healthcare IPO Review: Peer Comparison
Valuation Metrics
| Metric | FY23 | FY24 | FY25 (Pre-Issue) | FY25 (Post-Issue)* |
|---|---|---|---|---|
| EPS (INR) | 4.85 | 6.68 | 6.38 | 3.86 |
| P/E (X) | – | – | 13.5 – 14.3 | 22.3 – 23.6 |
| RONW (%) | 78.9 | 45.9 | 25.5 | – |
| NAV (INR) | 6.15 | 13.14 | 20.18 | – |
| ROCE (%) | 17.2 | 16.3 | 21.9 | – |
Peer Comparison
| Company | Revenue (INR Cr) | EPS (INR) | PE Ratio (X) | RONW (%) | Remarks |
|---|---|---|---|---|---|
| Anlon Healthcare | 120 | 6.38 | Large-scale, premium multiple | 25.5 | Smaller scale, improving margins |
| Kronox Lab Sciences | 100 | 6.9 | 26 | 28.3 | Similar size, higher valuation |
| Acutaas Chemicals | 1,007 | 19.8 | 58 | 12.1 | Large scale, premium multiple |
👉 At ~23x P/E, Anlon looks fairly priced vs Kronox and at a discount vs large peers like Acutaas.
Final Verdict
This Anlon Healthcare IPO review shows a company with:
✅ Strong niche in APIs like Loxoprofen Sodium Dihydrate.
✅ Broad product pipeline for scalability.
✅ Healthy margins, strong balance sheet, high ROCE.
✅ Positioned to benefit from China+1 shift.
But risks remain:
⚠️ Very low export share despite filings.
⚠️ Overdependence on a few customers & suppliers.
⚠️ Competition from larger domestic & global players.
For more details related to IPO GMP, SEBI IPO Approval, and Live Subscription stay tuned to IPO Central.